Get the Stockscreener App
3.50
0.57%
-0.02
After Hours:
3.50
Alvotech stock is traded at $3.50, with a volume of 208.21K.
It is down -0.57% in the last 24 hours and down -4.11% over the past month.
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.
See More
Previous Close:
$3.52
Open:
$3.57
24h Volume:
208.21K
Relative Volume:
0.40
Market Cap:
$1.09B
Revenue:
$563.46M
Net Income/Loss:
$27.92M
P/E Ratio:
36.31
EPS:
0.0964
Net Cash Flow:
$-146.33M
1W Performance:
-0.57%
1M Performance:
-4.11%
6M Performance:
-28.28%
1Y Performance:
-57.98%
1-Day Range:
$3.465
$3.61
1-Week Range:
$3.30
$3.61
52-Week Range:
$3.03
$11.85
Alvotech Stock (ALVO) Company Profile
Compare ALVO vs TAK, ZTS, TEVA, HLN, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALVO
Alvotech
|
3.50 | 1.10B | 563.46M | 27.92M | -146.33M | 0.0964 |
TAK
Takeda Pharmaceutical Co Adr
|
16.55 | 52.32B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
112.54 | 47.38B | 9.47B | 2.67B | 2.28B | 6.0218 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.86 | 41.16B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.17 | 41.02B | 14.54B | 2.22B | 2.58B | 0.4871 |
UTHR
United Therapeutics Corp
|
572.20 | 24.67B | 3.18B | 1.33B | 1.04B | 27.90 |
Alvotech Stock (ALVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Initiated | Barclays | Underweight |
| Nov-04-25 | Downgrade | Deutsche Bank | Buy → Hold |
| Oct-14-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-23-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-14-25 | Initiated | UBS | Buy |
| Jan-29-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Upgrade | Citigroup | Sell → Neutral |
| Sep-21-23 | Initiated | Barclays | Equal Weight |
| Sep-07-22 | Initiated | Morgan Stanley | Equal-Weight |
| Sep-06-22 | Downgrade | Citigroup | Buy → Sell |
| Jul-26-22 | Initiated | Citigroup | Buy |
View All
Alvotech Stock (ALVO) Latest News
Alvotech SA expected to post earnings of 2 cents a shareEarnings Preview - TradingView
Alvotech Announces General Counsel Transition After Six-Year Tenure - TipRanks
[6-K] Alvotech Current Report (Foreign Issuer) | ALVO SEC FilingForm 6-K - Stock Titan
Will Alvotech's (ALVO) Legal Transition and Executive Move to Reykjavik Quietly Reframe Its Governance Story? - simplywall.st
Earnings Preview: Alvotech to Report Financial Results Post-market on May 06 - 富途牛牛
Deutsche Bank Downgrades Alvotech (ALVO) - MSN
Alvotech Announces a Change in its Executive Team - The Manila Times
Alvotech : General MeetingALVOTECH - marketscreener.com
Alvotech (ALVO) to Release Quarterly Earnings on Wednesday - MarketBeat
Alvotech (NASDAQ:ALVO) Trading 7.1% HigherStill a Buy? - MarketBeat
Why is ALVO stock rising pre-market today? - MSN
Alvotech’s AVT03 approved by European Commission as biosimilar to Prolia and Xgeva - MSN
Dr Reddy's, Alvotech join hands to co-develop, manufacture & commercialise biosimilar of Merck's blockbuster drug Keytruda - MSN
Alvotech CCO Anil Okay steps down to become Adalvo CEO - MSN
Alvotech stock slides as FDA issues CRL for AVT05, company cuts EBITDA outlook - msn.com
Alvotech (ALVO) Valuation Gap Under Review After Mixed Share Performance And Biosimilar Pipeline Progress - Yahoo Finance
Alvotech to Report Financial Results for the First Quarter of 2026 - marketscreener.com
Alvotech to Announce First Quarter 2026 Financial Results and Host Webcast on May 7, 2026 - Quiver Quantitative
Biotech firm Alvotech sets May 6 earnings release, live Q&A next day - Stock Titan
Quant snapshot: Micron, Babcock & Wilcox lead strong buys as Fold Holdings, Alvotech lag - MSN
Alvotech : Inside Information / Ad Hoc InformationALVOTECH - marketscreener.com
Alvotech (NASDAQ:ALVO) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Here’s What the Street Thinks About Alvotech (ALVO) - Insider Monkey
Morgan Stanley Upgrades Alvotech (ALVO) - MSN
Wall Street Zen Upgrades Alvotech (NASDAQ:ALVO) to Hold - MarketBeat
Alvotech (NASDAQ:ALVO) Sees Significant Increase in Short Interest - MarketBeat
Alvotech stock (LU2557688560): Why does its biosimilar pipeline now matter more for U.S. investors? - AD HOC NEWS
Cash per share of Alvotech – DUS:Z45 - TradingView — Track All Markets
Alvotech Looks To Make Good On Two-Year Bet - Citeline News & Insights
ALVO SEC FilingsAlvotech 10-K, 10-Q, 8-K Forms - Stock Titan
ALVO Technical Analysis & Stock Price Forecast - Intellectia AI
Alvotech: Improving Fundamentals Signal Potential Bottom For This Biosimilar Player (ALVO) - Seeking Alpha
Retail Trends: Whats the outlook for Alvotech Equity Warrants sector2026 Snapshot & Safe Entry Trade Reports - baoquankhu1.vn
Alvotech’s Price Rises But Technical Signals Turn Bearish - Bitget
Performance Recap: Is Alvotech a top pick in the sector2026 Trade Ideas & Long-Term Growth Plans - baoquankhu1.vn
Why Is Alvotech (ALVOW) Stock Down Today? - Meyka
Alvotech stock: Biosimilar innovator with global growth potential - AD HOC NEWS
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Alvotech (NASDAQ:ALVO) Stock Price Down 9.5%Here's What Happened - MarketBeat
Alvotech Plummets 9.5% Amid Market Volatility and Sector Uncertainty - Bitget
Published on: 2026-04-07 05:57:03 - baoquankhu1.vn
Alvotech (NASDAQ:ALVO) Trading Up 7.2%Here's What Happened - MarketBeat
ETFs Investing in Alvotech Stocks - TradingView
Institution Moves: Is Alvotech stock overvalued or fairly pricedMarket Movers & Weekly High Return Forecasts - baoquankhu1.vn
Alvotech (NASDAQ:ALVO) Stock Rating Lowered by Wall Street Zen - MarketBeat
Alvotech Stock (ALVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.67%
2.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):